Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 19

Showing 19 citing articles:

JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 11
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 6
Nitrogen-Containing Heterocyclic Drug Products Approved by the FDA in 2023: Synthesis and biological activity
Weijiang Luo, Yiqi Liu, Hui Qin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116838-116838
Closed Access | Times Cited: 5
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management
Giovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 54-54
Open Access
Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Brett Hauber, Chiara Whichello, Jonathan Mauer, et al.
The Journal of Dermatology (2025)
Open Access
Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
Christos Tziotzios, Rodney Sinclair, Aleksandra Lesiak, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review
Jair Alejandro Valdez-Zertuche, Hassiel Aurelio Ramírez-Marín, Antonellá Tosti
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Mercedes E. González, John Edgar Browning, Stacy Smith, et al.
Pediatric Dermatology (2025)
Open Access
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Brett King, Paradi Mirmirani, Kristen Lo Sicco, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access
Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Samah Omar Ali Alfahl, Abdullateef A. Alzolibani
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1817-1817
Open Access
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata
Melissa Piliang, Jennifer Soung, Brett King, et al.
British Journal of Dermatology (2024)
Open Access | Times Cited: 2
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Samira Anderson, Guido Cavaletti, Linda J. Hood, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 1
Past, Present and Future Treatment of Alopecia Areata

Medical & Clinical Research (2024) Vol. 9, Iss. 4, pp. 01-06
Open Access
CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation
Shengjian Huang, Qian‐Jiao Yang, You Zhou, et al.
Transplant Immunology (2024) Vol. 85, pp. 102075-102075
Closed Access
A review of TEC family kinases and their inhibitors in the treatment of alopecia areata
Yinglin An, Fan Zhang
Archives of Dermatological Research (2024) Vol. 316, Iss. 8
Closed Access
Ritlecitinib in severe alopecia areata: a profile of its use
Matt Shirley
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 9, pp. 341-349
Open Access
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Jennifer Fu, Alexander Egeberg, S. Holmes, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 10, pp. 2759-2769
Open Access
▼Ritlecitinib for severe alopecia areata

Drug and Therapeutics Bulletin (2024) Vol. 62, Iss. 6, pp. 87-92
Closed Access
Innovation in Alopecia Areata
Luiza Kalil, Brett King
Dermatologic Clinics (2024) Vol. 43, Iss. 1, pp. 27-33
Closed Access
Page 1

Scroll to top